Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1995, for LecTec Corporation (Note: The request metadata listed "Axogen, Inc.", but the filing text explicitly identifies the registrant as LecTec Corporation). The company operates in the medical products sector, including medical tapes, conductive products, and therapeutic patches, with subsidiaries including Natus Corporation.
Key Financial Metrics
| Metric | Q1 1996 (Ended Sep 30, 1995) | Q1 1995 (Ended Sep 30, 1994) |
|---|---|---|
| Total Revenues | $3,462,451 | $2,904,523 |
| Gross Profit | $1,339,204 | $1,347,309 |
| Gross Margin | 38.7% | 46.4% |
| Operating Profit (Loss) | ($113,319) | $80,799 |
| Net Earnings (Loss) | ($95,366) | $78,936 |
| EPS (Basic/Diluted) | ($0.03) | $0.02 |
| Cash and Equivalents | $419,428 | $374,466 |
| Working Capital | $4,532,574 | $4,490,796 |
| Current Ratio | 3.84 | 4.34 |
| Long-term Debt | $0 | $0 |
| Notes Payable (Current) | $83,595 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 19.2% year-over-year, driven by a 73.9% surge in medical tape sales (new product and major retail customer) and a 30.9% increase in therapeutic products. This was partially offset by a 2.4% decline in conductive product sales due to delayed orders.
- Profitability Decline: Despite higher revenue, the company reported a net loss of $95,366 compared to a net profit of $78,936 in the prior year. Gross margin compressed from 46.4% to 38.7% due to a sales mix shift toward lower-margin tape products and increased raw material costs.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose to $941,490 (from $789,290) due to restructuring costs at the Natus subsidiary. R&D expenses increased to $511,033 (from $477,220) primarily for a non-nicotine smoking cessation product.
- Cash Flow: Net cash used in operating activities was $372,876, a significant improvement from the $745,690 used in the prior year, though still negative. Investing activities consumed $173,691 for capital expenditures.
Outlook, Risks, and Management Commentary
- Capital Expenditures: Management estimates capital expenditures will approach $3,300,000 for fiscal 1996, financed by operations. Recent spending included new production lines for medical tape and therapeutic products.
- Liquidity: The company maintains a $1,000,000 line of credit and reports a strong balance sheet with no long-term debt. The current ratio remains healthy at 3.84.
- Risks and Contingencies: The filing notes no pending legal proceedings. The primary operational risk highlighted is the impact of sales mix shifts on margins and the costs associated with restructuring the direct selling organization.
- Unusual Items: The liquidation of short-term investments to finance acquisitions and working capital needs reduced interest and dividend income.
Investor Verification Checklist
- Verify the sustainability of the 73.9% growth in medical tape sales and the retention of the "major new retail customer."
- Assess the timeline for the restructuring of the Natus subsidiary's direct selling organization and its impact on future SG&A expenses.
- Confirm the development status and regulatory pathway for the non-nicotine smoking cessation product driving R&D costs.
- Monitor raw material cost trends to determine if the 38.7% gross margin is a new baseline or a temporary compression.
- Review the utilization of the $1,000,000 line of credit given the negative operating cash flow.